US FDA expands approval to GSK’s Arexvy for adults aged 50-59, at increased risk EP News Bureau Jun 10, 2024 The RSV vaccine adjuvanted is currently approved for use in adults aged 60 and older and recommended by CDC/ACIP using shared…
